Multidisciplinary evaluation, including thoracic surgical consultation, is crucial for oligometastatic NSCLC patients to optimize treatment strategies. Lung surgery for oligometastatic NSCLC shows ...
Breakthrough research presented at the 2026 Society of Thoracic Surgeons Annual Meeting shows that additional lymph node evaluation is needed during surgery for non-small cell lung cancer (NSCLC) to ...
In this JCO Article Insights episode, Dr. Joseph Matthew interviews authors Dr. Yang Zhang and Dr. Haiquan Chen about their recently published JCO article, "Phase III Study of Mediastinal Lymph Node ...
Breakthrough research presented at the 2026 Society of Thoracic Surgeons Annual Meeting shows that additional lymph node evaluation is needed during surgery for non-small cell lung cancer (NSCLC) to ...
Recent evidence suggests that postoperative adjuvant radiotherapy (PORT) may enhance survival outcomes in patients with pN2 non-small cell lung cancer (NSCLC), particularly when analyzed through ...
Rybrevant plus Lazcluze significantly extends overall survival in EGFR-mutated NSCLC compared to Tagrisso, with benefits continuing beyond the follow-up period. The combination therapy improves ...
A rare subset of non-small cell lung cancer (NSCLC) patients have lung-only metastatic disease despite multiple lines of treatment. In this prospective study, estimated survival at 1 year was longer ...
Lung cancer is still the top cancer killer, but new developments are shifting what the future might hold for patients.
Lung transplant can extend survival in some patients with stage 4 lung cancer, according to a study published July 8 in JAMA. Researchers and physicians from Chicago-based Northwestern Medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results